HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic
structure of biguanide in metformin, an existing diabetes drug.
The immune modulating activity of HL237 was demonstrated in animal model. HL237 is a STAT3
inhibitor and STAT3 is well known for an important regulator inhibiting Th17 cells and
activating Treg cells.
Therefore, when STAT3 activity is inhibited, it is expected to be able to treat autoimmune
diseases such as rheumatoid arthritis.
This is the first repeated administration clinical trial performed for the development of
HL237 and is intended to evaluate the safety, tolerability and pharmacokinetics of each dose
group.